Epidemiology and prevention of hepatocellular carcinoma

Cancer Lett. 2009 Dec 1;286(1):5-8. doi: 10.1016/j.canlet.2008.10.046. Epub 2008 Dec 12.


A meta-analysis on the seroprevalence of hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV) in 27881 hepatocellular carcinomas from 90 studies confirmed wide international variations. A predominance of HBsAg was found in hepatocellular carcinomas from most Asian, African and Latin American countries, but anti-HCV predominated in Europe, North America, Japan, Pakistan, Mongolia, and Egypt. Anti-HCV was found more often than HBsAg in Europe and the United States. Twenty-five years after having been licensed, HBV vaccination programmes are now carried out in 158 countries, but they have yet to reach many high-risk populations in sub-Saharan Africa and Asia. In the absence of a vaccine, the prevention of HCV infection requires an integrated strategy (i.e., screening of blood donations, safe injection practices, and avoidance of unnecessary injections).

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / epidemiology*
  • Carcinoma, Hepatocellular / prevention & control*
  • Hepatitis B / complications
  • Hepatitis B / prevention & control
  • Hepatitis C / complications
  • Hepatitis C / prevention & control
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / epidemiology*
  • Liver Neoplasms / prevention & control*